Eisai Seeks PMDA Approval for Subcutaneous Formulation of Alzheimer’s Drug Leqembi

Eisai has submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) seeking approval for a subcutaneous formulation of Leqembi (lecanemab). The proposed formulation would provide an alternative administration route for the drug, which is currently delivered intravenously. The application is supported by data collected from multiple subcutaneous administration sub-studies conducted as part of the Phase III Clarity trial.

The Phase III Clarity trial investigated the efficacy and safety of lecanemab in treating Alzheimer’s disease. Within this study, Eisai conducted several sub-studies focusing on subcutaneous delivery methods to evaluate their potential as a new option for patients. The findings from these studies form the basis of Eisai’s submission to PMDA, aiming to expand treatment options for individuals requiring this medication.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: Got it! Please provide the date you’d like me to format.

Related posts:

Biopharma Bypasses Analysts: Direct Data Platforms Enable Real-Time Access to Clinical Trial & Market Research Data New Drug Identified by Researchers to Target Alzheimer’s and Neurodegenerative Diseases Affecting 55 Million Worldwide Cathepsin S Identified as a Regulator of Cancer Cell Energy Metabolism Pancreatic Tumors Found to Form Synapse-Like Structures to Utilize Neurotransmitters for Growth

Author

GOAI